3种短程三联疗法根除幽门螺杆菌感染的疗效比较  

Comparison of three kinds of short-term triple therapies for eradication of Helicobacter pylori infection

作　　者：吴楠[1] 王寿九[1] 王盛根[1] 潘桂红[1] 

机构地区：[1]中国人民解放军414医院消化内科,江苏南京210015

出　　处：《中国新药与临床杂志》2002年第11期655-657,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的 :比较 3种短程三联疗法根除幽门螺杆菌 (Hp)的疗效及不良反应。方法 :2 78例Hp阳性的消化性溃疡或慢性糜烂性胃窦炎病人分为 3组。A组 94例 ,以奥美拉唑 2 0mg ,po ,bid× 7d ;B组 82例 ,以兰索拉唑 30mg ,po ,qd× 7d ;C组10 2例 ,以泮托拉唑 4 0mg ,po ,qd× 7d。 3组均加用阿莫西林 10 0 0mg ,po ,bid× 7d及甲硝唑 4 0 0mg ,po ,bid× 7d。疗程结束 1mo后 ,复查胃镜及Hp。结果 :A ,B ,C组Hp根除率分别为 85 % ,88% ,89.2 % ;不良反应率分别为 2 8% ,2 4 % ,30 .4 % ,但均能耐受 ;组间比较P >0 .0 5。结论 :这3种三联疗法根除Hp均有良好疗效 ,且根除率相近 。AIM: To compare the effects and adverse reactions for the eradication of Helicobacter pylori (Hp) infection with three short-term triple therapies. METHODS: Two hundred seventy-eight patients with Hp associated with peptic ulcer or chronic erosive antral gastritis were divided into three groups. Group A (n=94; M 71, F 23; age 48 a± s 15 a) was treated with omeprazole 20 mg, po, bid×7 d. Group B(n=82; M 62, F 20; age 47 a±12 a) was treated with lansoprazole 30 mg, po, qd×7 d. Group C(n=102; M 78, F 24; age 45 a±13 a) was treated with pantoprazole 40 mg, po, qd×7 d. Three groups patients received amoxicillin 1 000 mg, po, bid×7 d and metronidazole 400 mg, po, bid×7 d. One month after anti-Hp therapy endoscopy and biopsies for histology, rapid urease test, 14C-urea breath test were repeated. RESULTS: The eradication rates of group A, group B, and group C were 85 %, 88 % and 89.2 %, respectively. Adverse reactions occurred in twenty-six patients of group A (28 %), in twenty patients of group B (24 %), and in thirty-one patients of group C (30.4 %), but well tolerated. The results among group A, group B, and group C show no significant difference (P>0.05). CONCLUSION: The three short-term tripe therapies are highly effective, without severe adverse reactions for eradication of Hp infection.

关 键 词：三联疗法 幽门螺杆菌感染 泮托拉唑 奥美拉唑 兰索拉唑 阿莫西林 甲硝唑 药物疗法 

分 类 号：R573[医药卫生—消化系统] R975[医药卫生—内科学]